ChiCTR-INR-16010047
结束
/
/
/
2016-11-25
/
/
鼻鼽(過敏性鼻炎症狀)
針刺聯合穴位敷貼治療鼻鼽(過敏性鼻炎症狀)的隨機對照臨床試驗
針刺聯合穴位敷貼治療鼻鼽(過敏性鼻炎症狀)的隨機對照臨床試驗
To determine the clinical effectiveness of either acupuncture combined with herbal moxibustion or acupuncture alone when compared to waiting list for patients with allergic rhinitis symptoms, measured by the improvement of nasal condition, quality of life, and serum IgE level.
随机平行对照
治疗新技术
Randomized
Single-blind on Investigator/research team
NA
/
0;48
/
1990-01-01
1990-01-01
/
1. Medical history: the subject has a history of allergic rhinitis, which is related to change in temperature and allergens such as pollen, dust mites, etc; 2. Clinical symptoms: the subject has the primary symptoms of nasal congestion, runny nose, sneezing and nasal itchiness. Subjects must have two or more of these symptoms; 3. Aged between 18 - 65; 4. A Total Nasal Symptom Score (TNSS) ≥ 4; 5. The subject agrees to take part in this study and is fully capacitated, can express personal will and accurately describe symptoms.;
请登录查看1. Has undertaken Chinese medicine treatment related to allergic rhinitis over the past month; 2. Has contracted respiratory infection or acute paranasal sinusitis within the past 14 days; 3. Has a history of chronic paranasal sinusitis; 4. Has organic nasal pathological changes or has had nasal surgeries; 5. Has asthma and other respiratory attack conditions; 6. Has taken antihistamines, steroids, decongestants (used on the nose, the mouth and the eyes), antibiotics, anti-coagulant and anti-platelet agents in the past month; 7. Has undertaken specific immune treatment or systemic hormone therapy in the past year; 8. Has serious cardiac, liver, renal, cerebrovascular conditions, or neural or mental disorders, etc.; 9. Be pregnant or nursing, or planning to conceive during the course of treatment; 10. Has G6PD; 11. Has wounds at the punctured locations or diabetes mellitus.;
请登录查看Department of Chinese Medicine, Hospital Authority
/
Department of Chinese Medicine, Hospital Authority的其他临床试验
Nethersole Chinese Medicine Service cum The Chinese University of Hong Kong Chinese Medicine Clinical Training and Research Centre的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示:#脐带间充质干细胞(#hUC-MSCs)
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点,索弗度肽(survodutide)成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构:国家卫生健康委办公厅、 2026-11-10
-
颁布机构:国家卫健委(原国家卫计委) 2026-11-10
-
颁布机构:国家药品审评中心(CDE) 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构:国家市场监督管理总局 2026-11-07
-
颁布机构:国家市场监督管理总局 2026-11-07
-
颁布机构:国家市场监督管理总局 2026-11-04

